LAHAR MEHTA, MD

Lahar is Chief Medical Officer of Nura Bio, overseeing the progression of Nura Bio’s clinical programs across neurological diseases. Previously, he served as Senior Vice President and head of Global Clinical Development at Amylyx Pharmaceuticals, where he led clinical development and clinical pharmacology activities across several indications including amyotrophic lateral sclerosis (ALS). Lahar brings many years of clinical development leadership across pharmaceutical and biotech companies including Biogen, Amgen and Annexon Biosciences where he contributed to the successful execution of multiple proof of concept to pivotal trials and approvals notably the European full marketing authorization of fampridine (FAMPYRA™) for multiple sclerosis and US approval for eptinezumab (VYEPTI™) for migraine. 

Lahar earned his undergraduate degree from Washington University in St. Louis and his medical degree from Meharry Medical College in Nashville, following which he served as a General Medical Officer with the United States Navy. Lahar completed his neurology residency at the University of Utah and a fellowship in Neuroimmunology and Experimental Therapeutics at the University of Rochester.